NYSE American - Nasdaq Real Time Price USD

China Pharma Holdings, Inc. (CPHI)

0.3388 +0.0111 (+3.39%)
As of 1:27 PM EDT. Market Open.
Loading Chart for CPHI
DELL
  • Previous Close 0.3277
  • Open 0.3490
  • Bid 0.3301 x 1000
  • Ask 0.3335 x 800
  • Day's Range 0.3301 - 0.3441
  • 52 Week Range 0.3000 - 2.7000
  • Volume 223,546
  • Avg. Volume 441,145
  • Market Cap (intraday) 5.02M
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

www.chinapharmaholdings.com

231

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CPHI

Performance Overview: CPHI

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CPHI
43.53%
S&P 500
4.48%

1-Year Return

CPHI
82.63%
S&P 500
19.95%

3-Year Return

CPHI
98.97%
S&P 500
19.07%

5-Year Return

CPHI
98.06%
S&P 500
71.55%

Compare To: CPHI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CPHI

Valuation Measures

As of 4/19/2024
  • Market Cap

    5.11M

  • Enterprise Value

    8.32M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.17

  • Price/Book (mrq)

    0.69

  • Enterprise Value/Revenue

    1.19

  • Enterprise Value/EBITDA

    986.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -43.91%

  • Return on Assets (ttm)

    -10.04%

  • Return on Equity (ttm)

    -52.43%

  • Revenue (ttm)

    7.01M

  • Net Income Avi to Common (ttm)

    -3.08M

  • Diluted EPS (ttm)

    -0.9100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.42M

  • Total Debt/Equity (mrq)

    62.16%

  • Levered Free Cash Flow (ttm)

    -168.57k

Research Analysis: CPHI

Fair Value

Overvalued
% Return
0.3388 Current
 

Earnings

Consensus EPS
 

People Also Watch